- 01Vyleesi was tested for one narrow kind of low desire; a PT-141 vial was tested for nothing
The trials behind Vyleesi enrolled premenopausal women whose low desire had lasted, distressed them, and had been checked for other causes such as medicines, depression, relationship strain or illness 1. In those women it moved desire a little and caused nausea in 4 of 10 1 2. A vial or nasal spray labelled PT-141 shares the molecule's name but none of that testing: no tested dose for the form, no checked purity, and no desire trial in men.
If you searched PT-141, you are looking at three products that share one molecule, bremelanotide: Vyleesi, the approved injection; compounded bremelanotide from a pharmacy; and 'research' vials and nasal sprays bought online. Only Vyleesi has been tested in people at a known dose and purity, and only in premenopausal women. In its two phase 3 trials it raised desire 0.35 points more than placebo on a 1.2-to-6 scale, and 4 in 10 women had nausea 1 2.
The three forms of PT-141
| Form | Status | Who it was tested in | Dose and quality control |
|---|---|---|---|
| Vyleesi (bremelanotide injection) | FDA-approved, prescription only, since June 2019 1 | Premenopausal women with low desire and distress 2 | A fixed, tested 1.75 mg dose in a single-use autoinjector, made to FDA manufacturing standards 1 |
| Compounded bremelanotide | Prescription, often through telehealth; the ingredient is approved, the compounded product is not | Not tested as its own product | Copies the approved dose, unverified; quality depends on the pharmacy |
| 'Research' PT-141 vials and nasal sprays | Not approved for any human use; no approved nasal product exists | Never tested in these forms | None tested; identity, strength and sterility unchecked |
What is PT-141, and is it the same as bremelanotide and Vyleesi?
Yes: PT-141 was Palatin Technologies' development code for bremelanotide, and gray-market sellers still use it. Vyleesi is the brand of the approved injection 1. Bremelanotide is a ring-shaped peptide seven amino acids long that copies alpha-MSH (alpha-melanocyte-stimulating hormone), a signal the body makes to switch on melanocortin receptors, a family of receptors that help control appetite, skin color and sexual behavior. It activates several of them, including MC3R and MC4R in the brain and MC1R, the receptor in pigment cells that darkens skin 1 8. Injected under the skin, close to 100% of a dose reaches the blood, and blood levels peak about 1 hour later 1.
PT-141 began as a tanning peptide
Bremelanotide descends from Melanotan II, a tanning peptide made by University of Arizona researchers. In a small trial there, Melanotan II produced erections in men, and Palatin built PT-141 from it 7 9. The Melanotan II page covers the tanning peptide and the risks of the versions still sold online.
- 11998: Melanotan II in menIn a double-blind crossover trial, Melanotan II produced erections in 8 of 10 men with erectile dysfunction that had no physical cause; nausea and yawning were common 7.
- 2Early 2000s: PT-141 as a nasal sprayPalatin tested PT-141 as a nasal spray for erectile dysfunction in healthy men and men with erectile dysfunction 8 9.
- 32008: the nasal program stopsPalatin dropped the nasal spray after rises in blood pressure, and moved to an injection under the skin for low desire in premenopausal women 9.
- 42015 to 2016: the RECONNECT trialsTwo phase 3 trials enrolled 1,267 premenopausal women 2.
- 5June 2019: Vyleesi approvedFDA approves bremelanotide for premenopausal women with low desire that distresses them 1.
How does PT-141 work?
The label calls the condition Vyleesi treats hypoactive sexual desire disorder (HSDD): low desire that persists and causes distress. The label is also frank that the mechanism "by which VYLEESI improves HSDD in women is unknown" 1. In preclinical studies, bremelanotide switched on neurons in the hypothalamus, a brain region that regulates sexual behavior 8. Sildenafil (Viagra) and tadalafil (Cialis) work somewhere else entirely: they relax blood vessels in the penis, and they help only when arousal is already present. Flibanserin (Addyi), the other approved drug for HSDD in premenopausal women, is a daily pill that acts on serotonin and dopamine. The same melanocortin activity that may lift desire also explains bremelanotide's main side effects: nausea, flushing and, through MC1R, dark patches of skin.
| Bremelanotide (Vyleesi) | Sildenafil or tadalafil | Flibanserin (Addyi) | |
|---|---|---|---|
| Where it acts | Melanocortin receptors in the brain | Blood vessels in the penis | Serotonin and dopamine receptors in the brain |
| What it targets | Low desire | Erections, when desire is present | Low desire |
| How it is taken | Injection under the skin before sex | Pill before sex, or daily low-dose tadalafil | Pill every night |
| Approved for | Premenopausal women with distressing low desire (HSDD) 1 | Men with erectile dysfunction | Premenopausal women with distressing low desire (HSDD) |
| Main side effects | Nausea, flushing, headache, blood pressure rise 1 | Headache, flushing, stuffy nose | Dizziness, sleepiness, fainting with alcohol |
Does PT-141 work? What the trials found
Bremelanotide works a little, in the women it was tested in. The two RECONNECT trials randomly assigned 1,267 premenopausal women with HSDD, average age 39 and mostly from US sites, to bremelanotide or placebo for 24 weeks, used as needed before sex 2. Desire was scored on the desire domain of the Female Sexual Function Index (FSFI), which runs from 1.2 to 6. Distress was scored on item 13 of the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO), one question on how often low desire bothered the woman, from 0 (never) to 4 (always) 1.
| Outcome (pooled, 24 weeks) | Scale | Bremelanotide minus placebo |
|---|---|---|
| Desire (FSFI desire domain) | 1.2 to 6; higher is more desire | +0.35 points 2 |
| Distress about low desire (one question, FSDS-DAO item 13) | 0 to 4; lower is less distress | -0.33 points 2 |
| Satisfying sexual events | Count per month | No significant difference 1 |
Both results were statistically significant (P<.001), which means they were unlikely to be chance; statistical significance does not make an effect large 2. More women stopped bremelanotide than stopped placebo: 40% versus 13% in Study 1 and 39% versus 25% in Study 2. Side effects made 18% of women on bremelanotide stop, against 2% on placebo, with nausea the most common reason 1. Of the women who finished, 684 entered a 52-week open-label extension, in which everyone knew they were on the drug, and 272 completed it. In women on bremelanotide from the start, desire scores ended 1.25 to 1.30 points above where they began and distress 1.4 to 1.7 points lower, with no placebo group to compare against, and no new safety problems appeared 3. Both trials were funded by the companies developing the drug 2.
Across RECONNECT trial data from two prior publications and the current study, bremelanotide's benefits are statistically modest and limited to outcomes for which scant evidence of validity among women with HSDD exists.Spielmans and Ellefson, independent reanalysis, Journal of Sex Research, 2024 4
That reanalysis found that the desire and distress scales had questionable validity in women with HSDD, and that results on 8 of the 11 efficacy outcomes registered for the trials had never been published. On those, effects ranged from nil to small 4.
PT-141 for men
Bremelanotide is not approved for men, and the Vyleesi label says so 1. Most of the human evidence in men comes from the nasal erectile dysfunction program. The largest published trial tested nasal bremelanotide in 342 men with erectile dysfunction who had not responded to sildenafil, and reported a positive result in 33.5% versus 8.5% on placebo 5. In 2023 the Journal of Urology attached an expression of concern to that paper, a formal warning that the editors doubt its reliability 5. No published trial has tested bremelanotide for low desire in men.
Low desire in men usually has a cause that can be checked, and the low libido page goes through them. The hormonal ones are low testosterone, high prolactin (a pituitary hormone that suppresses sex drive) and thyroid disease; SSRI antidepressants and finasteride are common medicine causes. If a medicine you take may be the cause, raise it with the prescriber rather than stopping it. Desire and erections are separate problems; as that page puts it, "erection tablets such as sildenafil help blood flow and do not increase desire." The erectile dysfunction page covers the erection work-up. "Low testosterone is a two-part diagnosis," as the low testosterone page puts it: symptoms plus a low morning level confirmed on a second morning. The male hormone panel guide walks through each line of the results.
The low-desire checks in men
CalculatorFree testosterone calculatorHave total testosterone and SHBG (sex hormone-binding globulin) on your report? Work out free testosterone from them.Work it out No labs yet? The low testosterone questionnaire is a short first screen to take to your clinician.
How is PT-141 taken, and how long does it last?
Vyleesi is a 1.75 mg fixed-dose autoinjector, used under the skin of the belly or thigh at least 45 minutes before expected sex. The label limits use to one dose in 24 hours, advises against more than 8 doses a month, and tells women to stop after 8 weeks if desire has not improved 1. Bremelanotide's half-life, the time for blood levels to halve, is about 2.7 hours, but the label states that how long the effect on desire lasts was never established 1. Research vials and nasal sprays have no tested dose at all, and what is in them is unknown.
How Vyleesi is used, according to its label
PT-141 side effects
Nausea is the most common side effect and the main reason women stopped. In the trials it was worst with the first dose (21%) and fell to about 3% with later doses; 13% of women needed anti-nausea medicine and 8% quit because of it. The rates below are from the pooled phase 3 trials, as given in the label 1.
| Side effect | Bremelanotide | Placebo |
|---|---|---|
| Nausea | 40.0% | 1.3% |
| Flushing | 20.3% | 0.3% |
| Injection-site reactions | 13.2% | 8.4% |
| Headache | 11.3% | 1.9% |
| Vomiting | 4.8% | 0.2% |
Every dose of bremelanotide raises blood pressure by up to 6 mmHg systolic (the top number) and 3 mmHg diastolic (the bottom number) and lowers heart rate by up to 5 beats per minute. The rise peaks 2 to 4 hours after the dose and usually settles within 12 hours 1. If you have a blood pressure reading you are unsure about, the high blood pressure page explains what 130/80 and 140/90 mean.
Interactions and pregnancy
Bremelanotide sharply lowers blood levels of oral naltrexone, so the label says to avoid it in anyone taking naltrexone for alcohol or opioid dependence, where a weaker naltrexone effect raises the risk of relapse. Bremelanotide also slows stomach emptying for a while after each dose, which can blunt oral drugs that need to work quickly or reach a set level, such as some painkillers and antibiotics. Based on harm to the fetus in preclinical studies, the label advises effective contraception while using bremelanotide and tells women to stop it if they become pregnant 1.
Who the label rules out, and when to take extra care
- Anyone with high blood pressure that is not under control, or with known heart disease. The label also advises against it for anyone at high risk of heart disease, and asks prescribers to make sure blood pressure is well controlled before starting 1.
- Anyone who is pregnant; the label advises effective contraception while using it 1.
- Anyone taking oral naltrexone for alcohol or opioid dependence 1.
- Men and postmenopausal women, who are outside the approval and were not studied for it 1.
- Anyone planning to use it more often than the label allows, given the dark-patch figures above 1.
Is PT-141 legal and FDA-approved?
Bremelanotide is FDA-approved only as Vyleesi, a prescription drug for one group of patients. The label states that Vyleesi is not indicated for postmenopausal women, for men, or "to enhance sexual performance" 1. Compounded drugs do not go through FDA approval, so compounded bremelanotide is only as good as the pharmacy that makes it. Vials and nasal sprays labelled 'research use only' or 'not for human consumption' are not approved for people, and the three forms table above sets out what is known about each. Athletes in tested sport should check the current World Anti-Doping Agency list with their anti-doping organization before using any peptide.
Before any desire drug: why desire drops and what to check
The Vyleesi label limits use to low desire with no other cause:
Low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: a co-existing medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug substance.
The International Society for the Study of Women's Sexual Health (ISSWSH) recommends the same order: screen for medical, psychiatric, medication, relationship and hormonal contributors before diagnosing and treating HSDD 6. The common causes are SSRI antidepressants and some other medicines, depression and stress, relationship strain, pain with sex, perimenopause and menopause, thyroid disease, high prolactin and poor sleep. The low libido page goes through each one.
Blood tests help with the hormonal causes. TSH (thyroid-stimulating hormone) screens for thyroid disease, and the guide on how to read a thyroid panel explains the results. Prolactin checks for a pituitary cause. Estradiol with FSH (follicle-stimulating hormone) shows where a woman is in the menopause transition; "Cycle day decides the reading," as the female hormone panel guide puts it, and the page on which cycle day to test gives the timing. A blood pressure check matters before any melanocortin drug. Desire often falls in perimenopause, and Vyleesi is approved only before menopause, so the perimenopause check is a useful first step for women in their 40s. A clinician who can see the whole picture, including the results, medicines and blood pressure, is the one to decide whether any desire treatment fits.
Hormone tests to read beside low desire
Other options have evidence behind them. ISSWSH lists sex therapy and couples work, a change to a medicine that dampens desire, and flibanserin for premenopausal women 6. A medicine change is for the prescriber to make, because stopping an antidepressant suddenly can cause withdrawal symptoms or a relapse. For postmenopausal women with HSDD, testosterone at doses that keep blood levels in the premenopausal range has evidence 6 10; no testosterone product is FDA-approved for women in the US, so this is off-label use that a clinician prescribes and monitors. The menopause page and the hormone therapy page cover the wider hormone options. For men with erectile dysfunction, PDE5 inhibitors, the pill class that includes sildenafil and tadalafil, restore the erection but not its cause; they are prescription drugs that must not be combined with nitrates, so a clinician decides whether they suit you.
Free, no accountRead your blood testHave hormone results from a low-desire work-up? Read every line of them and see what stands out.Read my results
Citations
- Vyleesi (bremelanotide injection) prescribing information. US Food and Drug Administration, 2019.
- Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstetrics & Gynecology, 2019;134(5):899-908.
- Simon JA, Kingsberg SA, Portman D, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstetrics & Gynecology, 2019;134(5):909-917.
- Spielmans GI, Ellefson EM. Small effects, questionable outcomes: bremelanotide for hypoactive sexual desire disorder. Journal of Sex Research, 2024;61(4):540-561.
- Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. Journal of Urology, 2008;179(3):1066-1071 (expression of concern, 2023).
- Clayton AH, Goldstein I, Kim NN, et al. The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women. Mayo Clinic Proceedings, 2018;93(4):467-487.
- Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Journal of Urology, 1998;160(2):389-393.
- Molinoff PB, Shadiack AM, Earle D, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 2003;994:96-102.
- Dhillon S, Keam SJ. Bremelanotide: first approval. Drugs, 2019;79(14):1599-1606.
- Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. Journal of Clinical Endocrinology & Metabolism, 2019;104(10):4660-4666.
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.





